|
Apr 2
|
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
|
|
Jan 10
|
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
|
|
Dec 20
|
Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
|
|
Dec 18
|
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine
|